|
1
|
Lodygin D, Epanchintsev A, Menssen A,
Diebold J and Hermeking H: Functional epigenomics identifies genes
frequently silenced in prostate cancer. Cancer Res. 65:4218–4227.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brigelius-Flohé R and Kipp A: Glutathione
peroxidases in different stages of carcinogenesis. Biochim Biophys
Acta. 1790:1555–1568. 2009.PubMed/NCBI
|
|
3
|
Yu YP, Yu G, Tseng G, et al: Glutathione
peroxidase 3, deleted or methylated in prostate cancer, suppresses
prostate cancer growth and metastasis. Cancer Res. 67:8043–8050.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mikata R, Yokosuka O, Fukai K, et al:
Analysis of genes upregulated by the demethylating agent
5-aza-2′-deoxycytidine in gastric cancer cell lines. Int J Cancer.
119:1616–1622. 2006.
|
|
5
|
Lee OJ, Schneider-Stock R, McChesney PA,
Kuester D, Roessner A, Vieth M, Moskaluk CA and El-Rifai W:
Hypermethylation and loss of expression of glutathione peroxidase-3
in Barrett’s tumorigenesis. Neoplasia. 7:854–861. 2005.PubMed/NCBI
|
|
6
|
Peng DF, Razvi M, Chen H, et al: DNA
hypermethylation regulates the expression of members of the
Mu-class glutathione S-transferases and glutathione peroxidases in
Barrett’s adenocarcinoma. Gut. 58:5–15. 2009.PubMed/NCBI
|
|
7
|
Zhang X1, Yang JJ, Kim YS, Kim KY, Ahn WS
and Yang S: An 8-gene signature, including methylated and
down-regulated glutathione peroxidase 3, of gastric cancer.
Int J Oncol. 36:405–414. 2010.PubMed/NCBI
|
|
8
|
Saga Y, Ohwada M, Suzuki M, et al:
Glutathione peroxidase 3 is a candidate mechanism of anticancer
drug resistance of ovarian clear cell adenocarcinoma. Oncol Rep.
20:1299–1303. 2008.PubMed/NCBI
|
|
9
|
Yang ZL, Yang L, Zou Q, et al: Positive
ALDH1A3 and negative GPX3 expressions are biomarkers for poor
prognosis of gallbladder cancer. Dis Markers. 35:163–172. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaiser MF, Johnson DC, Wu P, et al: Global
methylation analysis identifies prognostically important
epigenetically inactivated tumour suppressor genes in multiple
myeloma. Blood. 122:219–226. 2013. View Article : Google Scholar
|
|
11
|
El Haddad M, Jean E, Turki A, et al:
Glutathione peroxidase 3, a new retinoid target gene, is crucial
for human skeletal muscle precursor cell survival. J Cell Sci.
125:6147–6156. 2012.PubMed/NCBI
|
|
12
|
Barrett CW, Ning W, Chen X, et al: Tumor
suppressor function of the plasma glutathione peroxidase gpx3 in
colitis-associated carcinoma. Cancer Res. 73:1245–1255. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fitzpatrick JM, Schulman C, Zlotta AR and
Schröder FH: Prostate cancer: a serious disease suitable for
prevention. BJU Int. 103:864–870. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu J and Holmgren A: Selenoproteins. J
Biol Chem. 284:723–727. 2009. View Article : Google Scholar
|
|
15
|
Yang X, Deignan JL, Qi H, et al:
Validation of candidate causal genes for obesity that affect shared
metabolic pathways and networks. Nat Genet. 41:415–423. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bachtiary B, Boutros PC, Pintilie M, et
al: Gene expression profiling in cervical cancer: an exploration of
intratumor heterogeneity. Clin Cancer Res. 12:5632–5640. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He Y, Wang Y, Li P, Zhu S, Wang J and
Zhang S: Identification of GPX3 epigenetically silenced by
CpG methylation in human esophageal squamous cell carcinoma. Dig
Dis Sci. 56:681–688. 2011.
|
|
18
|
Scotto L, Narayan G, Nandula SV, et al:
Identification of copy number gain and overexpressed genes on
chromosome arm 20q by an integrative genomic approach in cervical
cancer: potential role in progression. Genes Chromosomes Cancer.
47:755–765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer - a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar
|
|
21
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
22
|
Christman JK: 5-Azacytidine and
5-aza-2′-deoxycytidine as inhibitors of DNA methylation:
mechanistic studies and their implications for cancer therapy.
Oncogene. 21:5483–5495. 2002.
|
|
23
|
Brigelius-Flohé R: Glutathione peroxidases
and redox-regulated transcription factors. Biol Chem.
387:1329–1335. 2006.PubMed/NCBI
|
|
24
|
Clark LC, Combs GF Jr, Turnbull BW, et al:
Effects of selenium supplementation for cancer prevention in
patients with carcinoma of the skin. A randomized controlled trial.
Nutritional Prevention of Cancer Study Group. JAMA. 276:1957–1963.
1996. View Article : Google Scholar
|
|
25
|
Dobosy JR, Roberts JL, Fu VX and Jarrard
DF: The expanding role of epigenetics in the development, diagnosis
and treatment of prostate cancer and benign prostatic hyperplasia.
J Urol. 177:822–831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jee CD, Kim MA, Jung EJ, Kim J and Kim WH:
Identification of genes epigenetically silenced by CpG methylation
in human gastric carcinoma. Eur J Cancer. 45:1282–1293. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maynard S, Schurman SH, Harboe C, de
Souza-Pinto NC and Bohr VA: Base excision repair of oxidative DNA
damage and association with cancer and aging. Carcinogenesis.
30:2–10. 2009. View Article : Google Scholar : PubMed/NCBI
|
